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T
o browse through old work is a pleasure in the indian
summer of a career, not devoid of nostalgia.As the large ma-
jority of our early work appeared inThrombosis and Diathe-
sis Haemorrhagica, the present issue is an appropriate occasion to
do so and to review old results, holding them against the light of
our present day knowledge – and apologising beforehand for the
shameless self-citation that it automatically involves.
Even in the mild light of hindsight this soon turns out to be
primarily an exercise in modesty and an occasion to recognise
old errors. Our early attempts to extract a maximum of informa-
tion from clotting times now may look a bit naïve.Yet some of the
conclusions and insights still seem to hold and still may con-
tribute to the understanding of what we now call the “initiation
phase” of blood coagulation.
My first contribution to Thrombosis and Diathesis Haem-
orrhagica was in the supplement that reported the proceedings
of the Gleneagles conference of the International Committee for
the Nomenclature of Blood Clotting Factors in 1963. It was on
PIVKA, protein induced by vitamin K absence(or antagonists)
and reports my first appearance before the big personalities of
coagulation of those days, such as Biggs, Brinkhous, Deutsch,
Koller, Macfarlane, Seegers and Soulier. From sheer anxiety my
right patella kept trembling during the full seven minutes that my
talk lasted. And nobody paid more than a polite interest – with
the notable exception of Peter Esnouf and François Josso.
My own initiation phase had begun some eight months be-
fore, when Fredi Loeliger had confronted me with a riddle in the
control of oral anticoagulation, viz. the discrepancy between
“prothrombin times” and single factor determinations. For those
who are so modern as to know clotting times only from figures
that come out of laboratory automatons, I will give some back-
ground information:
As everybody knows, the “prothrombin” defect in oral anti-
coagulation was, and still is, routinely assessed by the “pro-
thrombin time”, introduced by Armand Quick, often in a variant
introduced by Owren, i.e. with the addition of BaSO
4
adsorbed
cow-plasma, so as to make it dependent upon factors II, VII and
X only. (For a review see e.g. [1]). We used a variant in which we
added 0.1 ml of the plasma to be tested, 0.1 ml of BaSO
4
ad-
sorbed cow plasma that contained human brain thromboplastin
and recalcified at zero time with 0.1 ml of a 100 mM CaCl
2
sol-
ution in buffer. The “prothrombin” of Quick had turned out, in
the meantime, to be a set of proteins but the “prothrombin time”
remained, although “thromboplastin time” is more exact. This
clotting time was recognised to be dependent upon the factors II,
VII and X (factor IX standing offside at the high thromboplastin
concentrations used).
Each of these factors can also be determined separately. In
that case one takes 0.1 ml of plasma deficient in the factor that
you want to determine; 0.1 ml of 1:10 diluted sample of the plas-
ma to be tested and 0.1 ml thromboplastin solution in 100 mM
CaCl
2
. The 1:10 dilution was necessary to prevent that the other
clotting factors present in the sample would influence the clot-
ting time and in order to cover a useful range of clotting times.To
relate clotting times to clotting factor concentrations, reference
lines were made: the clotting time (t
c
) at dilutions of normal plas-
ma, by definition containing 100% of each factor, were plotted,
on logarithmic paper, against the clotting factor concentration
and the clotting time obtained with an unknown sample was re-
lated to a concentration using this graph.
Loeliger had found that in stable oral anticoagulation the four
vitamin-K-dependent clotting factors were decreased to about
the same level when tested individually (2). But in a “prothrom-
bin time” type of experiment consistently about half of that con-
centration was found. Why? Was there an elusive, rate limiting
fifth vitamin-K-dependent clotting factor?
In 1962 none of the clotting factors had been isolated to pu-
rity. It was not even certain that all of them were proteins. Walter
Seegers and his school maintained that factors II, VII, IX and X
were different aspects of one and the same prothrombin (1).Anti-
bodies were not available, monoclonals did not exist. Clotting
factors were defined as an activity required to make blood clot
normally and that was congenitally absent in certain patients.
Factor X e.g. was the entity lacking in the plasma of Mr. Stuart
and obviously in every plasma that would not correct the defect,
like that of Mrs. Prower (1). Therefore the possibilities to ap-
proach the problem were in practice limited to juggling with clot-
ting times.
While doing this, I recalled the Lineweaver-Burke plot of
enzyme kinetics: inverse reaction velocity against inverse sub-
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Figure1:Thrombotest dilution curves. A) Mixture of cirrhosis plas-
ma and vitamin-k-deficient plasma. ●−● t-D plot of normal plasma;
− t-D plot of cirrhosis plasma; ⊗−⊗ t-D plot of vitamin-K-deficient
plasma; ❍−❍ t-D plot of a mixture of equal parts of cirrhosis plasma
and vitamin-k-deficient plasma. B) Mixture of dicumarol plasma and vit-
amin-k-deficient plasma. ●−● T-D plot of normal plasma; ⊗−⊗ t-D plot
of dicumarol plasma; − t-D plot of vitamin-K-deficient plasma; ❍−❍
t-D plot of a mixture of equal parts of dicumarol plasma and vitamin-
k-deficient plasma. (Printed with permission from ref. [10]).
A)
B)
strate concentration is a straight line. I reasoned that dilution is
an inverse concentration of whatever might be rate-limiting in a
clotting time. Also I thought that clotting times could be in-
versely related to clotting velocity – whatever “clotting velocity”
might in fact mean. So I made a plot of clotting time against plas-
ma dilution – the t-D plot. To my pleasant surprise it appeared to
be a straight line (Fig.1)!The intercept of this line and the abscis-
sa – always by analogy to the Lineweaver-Burke plot – then
should indicate a minimal clotting time (t
min
), i.e. the clotting
time that could not be further shortened by increasing clotting
factor concentrations. Indeed we found that, in patients in which
the clotting factors were low due to parenchymatous liver disease
without vitamin K deficiency, such dilution curves extrapolated
to roughly the same point as normal plasma did and that, logi-
cally, the slope of the line indicated the clotting factor content;
not, however, in vitamin K deficiency or in oral anticoagulation:
there the extrapolated minimum time was systematically much
longer (Fig.1).
We reasoned – after exclusion of a number of alternatives –
that an inhibitor of prothrombin conversion must be present. The
minimal clotting time then would represent infinite clotting fac-
tor concentration but infinite inhibitor concentration as well.
Further calculations and experiments showed that it should be a
competitive inhibitor. Logically, competitive inhibition suggests
a substrate analogue and therefore an analogue of prothrombin.
So we thought of a prothrombin-like protein induced by the lack
of functional vitamin K and we postulated a precursor of pro-
thrombin that escaped into the circulation because its final syn-
thesis step was blocked (3). It was a long shot, but a hit.
Alas we did not bring home more than half of the game. I was
so eager to demonstrate that the inhibitor was a prothrombin-like
protein that I made a fundamental mistake. It was considered a
very specific property of prothrombin to adsorb easily to bento-
nite, and so did our inhibitor. Prothrombin also was known to ad-
sorb to BaSO
4
but our inhibitor hardly would. In my zeal to stress
the similarities with prothrombin I added so much adsorbent that
it finally did. I did not mention the quantity used in the letter to
Nature and neither did I explore this difference further. What if I
had? With hindsight, it is infuriating that, at that moment, we did
not do the experiment that we published only in 1970, i.e. the ac-
tivation of the euglobulin fraction of plasma (to exclude anti-
thrombins) from orally anticoagulated patients (4).There we saw
that much more thrombin formed than could be accounted for by
the prothrombin content measured in a one-stage test. First, a
quick thrombin generation occurred, in proportion with the
amount of normal prothrombin present, thereafter a slow gener-
ation followed, well in excess of that amount, and obviously due
to the activation of an abnormal prothrombin. All the techniques
to do this simple experiment were already available in 1963, and
it would have taken a week to finish the experiments. If we had
done that, we would have shown that in plasma from orally anti-
coagulated patients two types of prothrombin existed, one deter-
mined in a one-stage clotting assay and readily adsorbed to
BaSO
4
, the other slowly converted and escaping notice in the
presence of antithrombins.This might have been more direct evi-
dence than the rather abstract kinetic reasoning, that indeed
could not convince everybody. Hendrik Dam himself e.g. re-
mained reluctant to accept our reasoning, because he could not
reproduce the PIVKA phenomenon in his chickens – for the
good reason that in chickens the precursor does not appear in the
circulation. In cows it does, but their PIVKAs have no inhibitory
properties. On the whole our hypothesis on the mode of action of
vitamin K was neither contradicted nor recognised as something
particularly worthwhile.
The real progress in the matter came in 1968, more than five
years after our letter, when Ganrot and Nilehn demonstrated two
types of prothrombin by immuno-electrophoresis (5) and got
Johan Stenflo interested in the problem, which, several years
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later, led to the discovery of gamma carboxy glutamic acid (see
further [6]). Here I must mention that already in 1965 François
Josso showed me immuno-electrophoretic experiments that rep-
resented two types of prothrombin that differed in Ca
++
-binding
but, regrettably, timely publishing was not among his numerous
qualities (7).
In the meantime we continued to try and apply enzyme kin-
etics to clotting times and published the results in a series of ar-
ticles: Kinetic aspects of the interaction of clotting factors
(8–15). The first of the series was an attempt to give an underly-
ing theory to the enzyme kinetics of clotting times. In itself it was
an amusing exercise to sort out the differences between classical
kinetics and that of blood clotting: no initial velocity measure-
ments but end-point measurements of product (fibrin), not
necessarily an excess of enzyme over substrate, no real blanks
because of the presence of residual amounts of clotting factor in
deficient plasmas etc. My error was not so much in pursuing this
line of research but very much in the forbidding way I presented
it. If I would have had the intention to scare away even the most
interested clotting physiologist or clinician I could not have done
better. That first article brought me a solid reputation of incom-
prehensibility that has haunted me for years. Upon rereading I
now primarily spot the junior scientist that wanted to show off.
Is there nevertheless anything that remains useful in this
series of articles? Perhaps yes. In the second article of the series
(9) we verified the validity of the straight line relationship be-
tween thromboplastin time and plasma dilution. To make our
point (rather our line), the experimental data were the mean of a
minimum of 50 clotting times each. Two times the standard devi-
ation of the mean fitted within the diameter of the dots in the
graphs. Just counting the experimental points in that article
shows that it must be based on the determination of well over
5,000 (hand made) clotting times. It left no doubt that the graph
of clotting time against the inverse of plasma concentration is a
straight line. There is no doubt either that nobody found this es-
pecially interesting. When some ten years later the comparison
of thromboplastins became an issue, the calculation (inter-
national normalized ratio, INR) was based on an assumed rec-
tilinear relationship between the logarithms of clotting time and
plasma concentration, which, in the mean time we had shown to
be distinctly S-shaped (12, 16).
As I said then, and still think today, “This finding of a simple
straight line relationship between clotting time and plasma dilu-
tion is by no means simple to explain” (9). It must tell something
about the kinetics of thrombin generation during the initiation
phase but what it told remained enigmatic. In the last article of
the series (15), which better should have come first, we showed
that clotting occurs when the area under the thrombin-time curve
attains a certain fixed value (at a given fibrinogen concen-
tration). A fixed amount of enzymatic “work” apparently is
required to obtain clotting. This foreshadows the endogenous
thrombin potential (ETP): The initiation phase is apparently a
micro-thrombin generation experiment in its own right, with
thrombin concentrations that are so low that they escape detec-
tion in a normal thrombin generation experiment.
The clotting time marks the moment when enough thrombin
has acted long enough to make fibrinogen clot. The straight t-D
curve therefore shows that the amount of thrombin formed be-
fore clotting occurs is proportional to the plasma dilution. This
may sound logical, but in fact it is not. In a normal thrombin gen-
eration experiment, i.e. in the production phase, the amount of
thrombin formed increases as plasma is diluted! At a 1:24 dilu-
tion as much free thrombin is formed as at 2:3 dilution, primarily
because both prothrombin and antithrombin are diluted (E. De
Smedt, to be published). This suggests that, under the conditions
of a “prothrombin time” measurement, antithrombin does not
play a role, which is in line with the observation that the throm-
boplastin time is hardly influenced by heparin and implies that
free thrombin hardly occurs during the initiation phase. Probably
(meizo-)thrombin will activate factor V on the phospholipid sur-
face, and probably most of the thrombin that gets into solution
immediately binds to fibrinogen and is not released when fibrin
is formed. The strong binding of thrombin to fibrin is long since
known (17), and the dependence of clotting time on the fibri-
nogen concentration is compatible with a reaction mechanism in
which the thrombin-fibrin intermediate does not dissociate but
converts another fibrinogen (8). As an aside, one may question
why then the activated partial thromboplastin time is influenced
by heparin? Elsewhere we argued that this is because thrombin in
free solution is an essential element in the generation of pro-
thrombinase as soon as factor VIII is involved in the mechanism
(see [18]).
In a further article of the “Kinetic aspects” series we com-
pleted and extended the experiments that led to the discovery of
PIVKA (12) and in a fourth one, as forbidding as the first one, we
treated the kinetics of competitive inhibition in clotting tests
(13).
The experiments thus far were on thromboplastin times, i.e.
on experimental systems, where the three factors II, VII and X
were diluted simultaneously. Next we wanted to investigate the
behaviour of the clotting time as a function of each of the factors
of the extrinsic system separately (14). This was complicated by
the fact that the deficient plasmas that were used as reagents
never were completely devoid of the deficient factor. The
reagent-plasma always would clot, even when not a trace or nor-
mal plasma was added. However, we found a trick to measure the
amount of residual factor in the deficient plasma and then could
show that the clotting time is inversely proportional to each of the
concentrations of the factors of the extrinsic system. Only years
later, when we could make completely deficient plasmas, we
were able to check that we had not been mistaken (16).
In the light of the inverse relation between clotting time and
the amount of thrombin formed (17), today I would simply inter-
pret these results to show that, in a thromboplastin-time type of
experiment, the amount of thrombin formed during the initiation
phase is proportional to the rate limiting clotting factor, whether
this is factor II, V, VII or X. In the original article we went into
great length to demonstrate that the relations found were not in
accordance with the original cascade hypothesis but required a
mechanism in which prothrombinase was a reversible stoichio-
metric product of Xa and Va and was inactivated during the clot-
ting process.
By that time, together with Macfarlane and Esnouf in Oxford,
we had found that prothrombinase formed as a reversible com-
plex of factors Va and Xa on phospholipid (21). It was natural
that we wanted to show that our results in plasma confirmed that
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